Telix and Cyclotek Conclude Radiopharmaceutical Manufacturing Agreement for Australia and New Zealand
Telix is pleased to announce the completion of a Master Services Agreement with Cyclotek (Aust) Pty Ltd (Cyclotek).
Abzena and Telix Sign Licence Agreement for Abzena’s Prostate-Specific Membrane Antigen Antibodies
Telix is pleased to announce a licence agreement collaboration with Abzena plc (Abzena) for its prostate-specific membrane antigen antibodies (PSMA).
Telix Pharmaceuticals and Atlab Pharma Conclude Therapeutic Product Development Agreement for Prostate Cancer
Telix is pleased to announce the completion of a product collaboration and purchase option agreement with Atlab Pharma SAS (Atlab).
Telix Pharmaceuticals Acquires Glioblastoma Program from Therapeia
Telix is pleased to announce a product development partnership with Therapeia GmbH & Co KG (“Therapeia”).
Wilex Signs Antibody License Agreement With Telix Pharmaceuticals Limited
Telix is delighted to have established this licensing agreement with Wilex for an important product with the potential to significantly impact cancer care.